KRAS and colonic neoplasm: DOPC (1,2-dioleoyl-sn-glycero-3- phosphatidylcholine) nanoliposomes loaded with Kras siRNAs have also been used in animal models of lung and colon cancer with success in decreasing metastases, but this platform did not selectively target a codon mutation [33].